TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12818245
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin (LMWH) administered in a fixed dose of 200 anti-Xa IU/kg body weight in one subcutaneous injection daily
Study: 10699698
Drug: Adult self-inflatable
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult self-inflatable bag (maximum volume, 1500 ml)
Study: 10699698
Drug: Paediatric self-inflatable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paediatric self-inflatable bag (maximum volume, 700 ml)
Study: 8418695
Drug: Intraoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiotherapy (IORT) administered to the gastric bed (20 Gy using 11 to 15 MeV electrons)
Study: 8418695
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (gastrectomy alone or resection and postoperative external beam radiotherapy to the upper abdomen (50 Gy using 6 to 10 mV photons))
Study: 30404599
Drug: Ultrasound-guided lumbar
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided lumbar facet joint injections
Study: 30404599
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose computed tomography (CT) guidance for lumbar facet joint injections
Study: 26293583
Drug: Silexan 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silexan 80 mg once daily for 10 weeks
Study: 23375194
Drug: Interceptor(®) Flavor
Normalized name: INTERCEPTOR
DrugBank: Milbemycin oxime (DB11531)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interceptor(®) Flavor Tabs(®) at a minimum dose of 0.5 mg/kg (0.23 mg/lb)
Study: 23375194
Drug: Sentinel(®) Flavor
Normalized name: Sentinel Flavor Tabs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sentinel(®) Flavor Tabs(®) at a minimum dose of 0.5 mg/kg (0.23 mg/lb)
Study: 30661197
Drug: Adalimumab treatment
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab treatment
Study: 8048859
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 1.0 mg/h of tissue plasminogen activator (group A)
Study: 8048859
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg bolus followed by an infusion of 1.0 mg/h of tissue plasminogen activator (group B)
Study: 2972631
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical nerve stimulation (TENS) and etofenamate 10% gel, 3‐5 cm daily on the day of TENS therapy, and the same dose twice daily on the other days
Study: 31216821
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy group
Study: 27486173
Drug: Aspiration thrombectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspiration thrombectomy after intravenous alteplase (IAT)
Study: 27486173
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase alone
Study: 21737235
Drug: Continuous veno-venous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous veno-venous hemodiafiltration (CVVHDF) and Intravenous furosemide
Study: 20009055
Drug: Tarenflurbil, 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tarenflurbil, 800 mg, administered twice a day
Study: 17335419
Drug: 0.2 mg/mL
Normalized name: iodine 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/mL rhBMP‐2
Study: 17335419
Drug: 0.05 mg/mL
Normalized name: digoxin 0.05 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/mL rhBMP‐2
Study: 11511121
Drug: Pentasaccharide (low,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentasaccharide (low, medium, or high dose) administered daily for 5 to 7 days, intravenously on the first day, then subcutaneously
Study: 7810083
Drug: Magnesium (Mg)
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (Mg) treatment with 50 mmol Mg for the first 24 hours and 12 mmol Mg for the subsequent 24 hours
Study: 29128507
Drug: Unloading shoes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unloading shoes (ASICS GEL‐Melbourne OA)
Study: 26878748
Drug: 1.2% Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2% Rosuvastatin Gel
Study: 26878748
Drug: 1.2% Atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2% Atorvastatin Gel
Study: 23883311
Drug: Terbutaline sulfate
Normalized name: Terbutaline Sulfate
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbutaline sulfate fast dissolving sublingual films
Study: 23883311
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral tablets
Study: 20664891
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of ethanol (35 g)
Study: 17716753
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of RV dilation and IVC broadening
Study: 17083839
Drug: Alpha-adrenoceptor agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-adrenoceptor agonists
Study: 11869839
Drug: Chronic lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic lisinopril therapy
Study: 11869839
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose of lisinopril
Study: 10022449
Drug: L‐T4 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐T4 treatment (group A, n = 100) with an initial dose of 150 microg daily
Study: 10022449
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (group B, n = 102)
Study: 7784246
Drug: DGAVP (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DGAVP (2 mg single dose)
Study: 7784246
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with DGAVP (1 mg/day for 2 weeks)
Study: 7784246
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with DGAVP
Study: 7784246
Drug: Acute treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute treatment with DGAVP
Study: 359246
Drug: Diflunisal 375
Normalized name: diflunisal 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal 375 mg or 500 mg
Study: 359246
Drug: Diflunisal (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (multiple doses)
Study: 359246
Drug: Oxyphenbutazone 200
Normalized name: oxyphenbutazone
DrugBank: Oxyphenbutazone (DB03585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxyphenbutazone 200 mg t.i.d.
Study: 29603100
Drug: Dietary zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary zinc intake (7.04 ± 4.28 mg/day)
Study: 25345953
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg, twice daily, n=36)
Study: 25345953
Drug: Acarbose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (50 mg, three times a day, n=30)
Study: 22707271
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (1.06 g)
Study: 20841390
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplement (1 mg/day)
Study: 3534570
Drug: Allopurinol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (100 mg three times daily)
Study: 29193558
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants (SIs), 6.5 to 8.5mm long
Study: 29193558
Drug: Sinus augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinus augmentation (SA) and implants ≥10mm long
Study: 29193558
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants (SIs)
Study: 29193558
Drug: Sinus augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinus augmentation (SA)
Study: 29193558
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants (SIs) and Sinus augmentation (SA)
Study: 27362788
Drug: Tenofovir (TFV)
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir (TFV) 1% gel
Study: 27362788
Drug: Placebo rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo rectal gel
Study: 24377326
Drug: Methylphenidate (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (low dose: 5 mg × 3)
Study: 24377326
Drug: Methylphenidate (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (normal dose: 20 mg × 3)
Study: 18370580
Drug: Weekly reflexology
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly reflexology treatments for 4 weeks
Study: 7949827
Drug: Proper diagnosis
Normalized name: Propel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proper diagnosis and treatment of hypertensive disorders in pregnancy
Study: 3056431
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg bid
Study: 3056431
Drug: Clofibrate 1000
Normalized name: clofibrate 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibrate 1000 mg bid
Study: 19333169
Drug: Clonidine-bupivacaine nerve-stimulator
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine-bupivacaine nerve-stimulator guided injection (9 mL bupivacaine 0.5% and 1 mL clonidine 150 mcg/mL)
Study: 19333169
Drug: Bupivacaine guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine guided injection (9 mL bupivacaine 0.5% and 1 mL saline)
Study: 31780418
Drug: Clopidogrel as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel as mono antiplatelet therapy (MAPT) after COBRA PzF NCS implantation
Study: 28494920
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (2 mg/0.05 mL at baseline, 4 weeks, and 8 weeks; reviewed every 4 weeks thereafter with injections as needed)
Study: 25986590
Drug: Lithium plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium plus Treatment As Usual (TAU)
Study: 25986590
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus Treatment As Usual (TAU)
Study: 23870047
Drug: Internet administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Internet administration of the Edinburgh Depression Scale
Study: 23870047
Drug: Telephone administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone administration of the Edinburgh Depression Scale
Study: 23870047
Drug: Pen-and-paper administration
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pen-and-paper administration of the Edinburgh Depression Scale
Study: 21341893
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted one-session treatment (OST-CA)
Study: 21341893
Drug: Standard one-session
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard one-session treatment (OST-S)
Study: 17823446
Drug: Dairy intervention
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy intervention group (n = 39) receiving daily approximately 1200 mg Ca and 7.5 microg vitamin D3 via fortified dairy products and biweekly nutrition education sessions
Study: 17823446
Drug: Calcium‐supplemented group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium‐supplemented group (n = 26) receiving a total of 1200 mg Ca/d
Study: 15114779
Drug: Low-molecular heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular heparin dalteparin (n = 31)
Study: 15114779
Drug: Non-fractionated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fractionated heparin (n = 17)
Study: 9556902
Drug: Patch containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch containing 4.0 mg of E2 in a reservoir system
Study: 9556902
Drug: Patch containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch containing 1.8 mg of E2 in a specially designed matrix system
Study: 9556902
Drug: Matrix system
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix system patches
Study: 31722135
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of α-lipoic acid
Study: 25904367
Drug: Weekly rifapentine
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly rifapentine plus isoniazid (3HP)
Study: 25904367
Drug: Daily isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily isoniazid (9H)
Study: 19552744
Drug: Rabeprazole (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (7 days) with antibiotics (clarithromycin and amoxicillin) given on days 1-4, 4-7, or 1-7
Study: 15497665
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg test tablets
Study: 15497665
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg test tablets
Study: 15497665
Drug: Reference tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference tablets of the same strength (250 mg and 500 mg)
Study: 11456368
Drug: 89Sr‐chloride (527
Approvals — FDA: no, EMA: no, PMDA: no
Description: 89Sr‐chloride (527 treatments)
Study: 11456368
Drug: 186Re‐HEDP (83
Approvals — FDA: no, EMA: no, PMDA: no
Description: 186Re‐HEDP (83 treatments)
Study: 11456368
Drug: Retreatments (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retreatments (up to five injections, 100 total)
Study: 10923463
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg administered at 60 seconds
Study: 10923463
Drug: Rocuronium maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium maintenance (either intravenous infusion or bolus injection)
Study: 10923463
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg administered at 90 seconds
Study: 2499730
Drug: ubinon (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: ubinon (90 and 135 mg/day)
Study: 31829404
Drug: Primary tumour
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary tumour resection plus chemotherapy
Study: 24151394
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy alone (O‐G+t group)
Study: 24151394
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy and mouthrinse treatment (O+G+tm group)
Study: 24151394
Drug: Triple therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy, mouthrinse, and periodontal treatment (O+G+tmp group)
Study: 24151394
Drug: O‐G+t group
Approvals — FDA: no, EMA: no, PMDA: no
Description: O‐G+t group
Study: 24151394
Drug: O+G+t group
Normalized name: Padimate O
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: O+G+t group
Study: 24151394
Drug: O+G+tm group
Normalized name: Padimate O
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: O+G+tm group
Study: 24151394
Drug: O+G+tmp group
Normalized name: Padimate O
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: O+G+tmp group
Study: 21334096
Drug: Griseofulvin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin (mean duration of treatment 8 weeks, range 6‐12 weeks)
Study: 21334096
Drug: Terbinafine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (mean duration of treatment 4 weeks, range 2‐6 weeks)
Study: 17083726
Drug: Moderate-to-severe asthmatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-to-severe asthmatics on inhaled steroid treatment
Study: 15617307
Drug: Brimonidine 0.2%
Normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine 0.2% twice daily (BID) for 4 weeks
Study: 15617307
Drug: Brimonidine 0.2%
Normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine 0.2% three times daily (TID) for 4 weeks
Study: 7871001
Drug: tropisetron 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: tropisetron 0.5 mg daily
Study: 7871001
Drug: tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tropisetron 5 mg daily
Study: 7871001
Drug: tropisetron 25
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tropisetron 25 mg daily
Study: 7871001
Drug: tropisetron (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: tropisetron (all doses)
Study: 3531149
Drug: Other slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other slow-release theophylline formulation
Study: 30613992
Drug: PICC removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: PICC removal and PN discontinuation at an enteral feed volume of 100 mL/kg/day
Study: 30613992
Drug: PICC removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: PICC removal and PN discontinuation at an enteral feed volume of 140 mL/kg/day
Study: 22001758
Drug: Mechanical ventilation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical ventilation with tidal volume (V(T)) of 12 mL/kg ideal body weight with zero positive end‐expiratory pressure (PEEP)
Study: 22001758
Drug: Mechanical ventilation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical ventilation with tidal volume (V(T)) of 6 mL/kg ideal body weight with PEEP of 8 cm H(2)O
Study: 20810669
Drug: Metformin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (250 mg/d)
Study: 17953380
Drug: Preoperative preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative preparation method of sequential thyroid defunctionalization (subgroup A)
Study: 17953380
Drug: Preoperative preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative preparation method of sequential thyroid defunctionalization (subgroup B)
Study: 17953380
Drug: Preoperative preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative preparation method of sequential thyroid defunctionalization (subgroup C)
Study: 17953380
Drug: Preoperative preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative preparation method of sequential thyroid defunctionalization (subgroup D)
Study: 17953380
Drug: Preoperative preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative preparation method of sequential thyroid defunctionalization (test group)
Study: 17953380
Drug: Antithyroid drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drugs and iodine preparation (control group)
Study: 10219883
Drug: rec-GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rec-GH therapy (C=0.6 IU/kg/week for C, CO=0.5 IU/kg/week, A=0.25 IU/kg/week) for 12 months (C and A) and 6 months (CO)
Study: 10219883
Drug: rec-GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rec-GH therapy
Study: 1619179
Drug: Thiamin intake
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamin intake greater than or equal to 1.0 mg/day
Study: 1619179
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 intake at the current recommended dietary allowance (1.6 mg)
Study: 6322681
Drug: Ceftriaxone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (100 mg/kg per day in two doses for a minimum of 10 days)
Study: 6322681
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy (ampicillin and chloramphenicol or gentamicin, pending sensitivity)
Study: 25072436
Drug: DJBL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DJBL treatment with dietary intervention
Study: 17507105
Drug: sarpogrelate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: sarpogrelate (300 mg/day) plus aspirin (100 mg/day)
Study: 17507105
Drug: ticlopidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ticlopidine (200 mg/day) plus aspirin (100 mg/day)
Study: 16323175
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no voice therapy)
Study: 10664525
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor MPV 2213ad, single dose of 100mg
Study: 10664525
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor MPV 2213ad
Study: 7640644
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg.kg‐1) administered 2‐1/2 hrs prior to swim trial
Study: 7640644
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 2‐1/2 hrs prior to swim trial
Study: 2665027
Drug: Clenbuterol (0.0012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clenbuterol (0.0012 mg/kg/day) solution bid for one week
Study: 2665027
Drug: Terbutaline (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (0.075 mg/kg/day) solution tid
Study: 363071
Drug: Naprosyn (naproxen)
Normalized name: naproxen Oral Suspension [Naprosyn]
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naprosyn (naproxen) 750 mg daily
Study: 29229103
Drug: Budesonide/formoterol pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol pMDI 320/9 μg BID
Study: 29229103
Drug: Formoterol DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol DPI 9 μg BID